The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Real-world data modeling to evaluate cilta-cel in second vs third-line for refractory myeloma
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, presents findings from real-world data modeling evaluating the sequencing of CAR-T cell therapy and standard of care (SoC) in patients with lenalidomide-refractory multiple myeloma (MM). This analysis estimated overall survival (OS) from real-world data and highlighted that initiating CAR T-cell therapy with ciltacabtagene autoleucel (cilta-cel) earlier could yield improved survival outcomes, as evidenced by the 8.8-year OS if used in second-line versus 5.5 years if deferred to third-line. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
